APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Nimodipine Sustained Release Tablets

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Nimodipine Sustained Release Tablets Market Outlook and Growth Opportunities 2026

Report ID 174017100431 December 2025192 pages

Choose your research edition.

Industry ResearchNimodipine Sustained Release Tablets Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Nimodipine Sustained Release Tablets Industry Growth and Trends Forecast to 2032108 pages · $3,450 USDMarket StructureGlobal Nimodipine Sustained Release Tablets Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Nimodipine Sustained Release Tablets Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Nimodipine Sustained Release Tablets Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Nimodipine Sustained Release Tablets market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Nimodipine Sustained Release Tablets is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Nimodipine Sustained Release Tablets is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Nimodipine Sustained Release Tablets is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Nimodipine Sustained Release Tablets market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Nimodipine Sustained Release Tablets market include Arbor Pharmaceuticals, Bayer Vital, Bionpharma, Heritage Pharmaceuticals, Pharmaceutics International, Sofgen Pharmaceuticals, Wuhan HITECK Biopharmaceutical, Sihuan Pharmaceutical and Jiangsu Kanion Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Nimodipine Sustained Release Tablets market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Nimodipine Sustained Release Tablets and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Nimodipine Sustained Release Tablets sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Nimodipine Sustained Release Tablets market size, projected growth trends, production technologies, key applications, and end-use industries.

Nimodipine Sustained Release Tablets Segment by Company

Arbor Pharmaceuticals

Bayer Vital

Bionpharma

Heritage Pharmaceuticals

Pharmaceutics International

Sofgen Pharmaceuticals

Wuhan HITECK Biopharmaceutical

Sihuan Pharmaceutical

Jiangsu Kanion Pharmaceutical

Qilu Pharmaceutical

Shandong Yunmen Pharmaceutical

Yabao Pharmaceutical Group

Nimodipine Sustained Release Tablets Segment by Type

30mg/Piece

60mg/Piece

Others

Nimodipine Sustained Release Tablets Segment by Application

Hospital

Pharmacy

Others

Nimodipine Sustained Release Tablets Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Nimodipine Sustained Release Tablets status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Nimodipine Sustained Release Tablets market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Nimodipine Sustained Release Tablets significant trends, drivers, influence factors in global and regions.

6. To analyze Nimodipine Sustained Release Tablets competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Nimodipine Sustained Release Tablets market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Nimodipine Sustained Release Tablets and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Nimodipine Sustained Release Tablets.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Nimodipine Sustained Release Tablets market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Nimodipine Sustained Release Tablets industry.

Chapter 3: Detailed analysis of Nimodipine Sustained Release Tablets manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Nimodipine Sustained Release Tablets in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Nimodipine Sustained Release Tablets in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Nimodipine Sustained Release Tablets Industry Trends Table 2. Nimodipine Sustained Release Tablets Industry Drivers Table 3. Nimodipine Sustained Release Tablets Industry Opportunities and Challenges Table 4. Nimodipine Sustained Release Tablets Industry Restraints Table 5. Global Nimodipine Sustained Release Tablets Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Nimodipine Sustained Release Tablets Revenue Share by Company (2021-2026) Table 7. Global Nimodipine Sustained Release Tablets Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Nimodipine Sustained Release Tablets Sales Volume Share by Company (2021-2026) Table 9. Global Nimodipine Sustained Release Tablets Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Nimodipine Sustained Release Tablets Company Ranking, (2024-2026) & (USD Million) Table 11. Global Nimodipine Sustained Release Tablets Key Company Manufacturing Base & Headquarters Table 12. Global Nimodipine Sustained Release Tablets Company, Product Type & Application Table 13. Global Nimodipine Sustained Release Tablets Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Nimodipine Sustained Release Tablets by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of 30mg/Piece Table 18. Significant Companies of 60mg/Piece Table 19. Significant Companies of Others Table 20. Global Nimodipine Sustained Release Tablets Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 21. Global Nimodipine Sustained Release Tablets Sales Volume by Type (2021-2026) & (K Units) Table 22. Global Nimodipine Sustained Release Tablets Sales Volume by Type (2027-2032) & (K Units) Table 23. Global Nimodipine Sustained Release Tablets Sales Volume Share by Type (2021-2026) Table 24. Global Nimodipine Sustained Release Tablets Sales Volume Share by Type (2027-2032) Table 25. Global Nimodipine Sustained Release Tablets Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Nimodipine Sustained Release Tablets Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Nimodipine Sustained Release Tablets Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Nimodipine Sustained Release Tablets Sales Value Share by Type (2021-2026) Table 29. Global Nimodipine Sustained Release Tablets Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Hospital Table 31. Significant Companies of Pharmacy Table 32. Significant Companies of Others Table 33. Global Nimodipine Sustained Release Tablets Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 34. Global Nimodipine Sustained Release Tablets Sales Volume by Application (2021-2026) & (K Units) Table 35. Global Nimodipine Sustained Release Tablets Sales Volume by Application (2027-2032) & (K Units) Table 36. Global Nimodipine Sustained Release Tablets Sales Volume Share by Application (2021-2026) Table 37. Global Nimodipine Sustained Release Tablets Sales Volume Share by Application (2027-2032) Table 38. Global Nimodipine Sustained Release Tablets Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Nimodipine Sustained Release Tablets Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Nimodipine Sustained Release Tablets Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Nimodipine Sustained Release Tablets Sales Value Share by Application (2021-2026) Table 42. Global Nimodipine Sustained Release Tablets Sales Value Share by Application (2027-2032) Table 43. Global Nimodipine Sustained Release Tablets Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 44. Global Nimodipine Sustained Release Tablets Sales by Region (2021-2026) & (K Units) Table 45. Global Nimodipine Sustained Release Tablets Sales Market Share by Region (2021-2026) Table 46. Global Nimodipine Sustained Release Tablets Sales by Region (2027-2032) & (K Units) Table 47. Global Nimodipine Sustained Release Tablets Sales Market Share by Region (2027-2032) Table 48. Global Nimodipine Sustained Release Tablets Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Nimodipine Sustained Release Tablets Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Nimodipine Sustained Release Tablets Sales Value Share by Region (2021-2026) Table 51. Global Nimodipine Sustained Release Tablets Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Nimodipine Sustained Release Tablets Sales Value Share by Region (2027-2032) Table 53. Global Nimodipine Sustained Release Tablets Market Average Price (US$/Unit) by Region (2021-2026) Table 54. Global Nimodipine Sustained Release Tablets Market Average Price (US$/Unit) by Region (2027-2032) Table 55. Global Nimodipine Sustained Release Tablets Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Global Nimodipine Sustained Release Tablets Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Nimodipine Sustained Release Tablets Sales by Country (2021-2026) & (K Units) Table 58. Global Nimodipine Sustained Release Tablets Sales Market Share by Country (2021-2026) Table 59. Global Nimodipine Sustained Release Tablets Sales by Country (2027-2032) & (K Units) Table 60. Global Nimodipine Sustained Release Tablets Sales Market Share by Country (2027-2032) Table 61. Global Nimodipine Sustained Release Tablets Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Nimodipine Sustained Release Tablets Sales Value Market Share by Country (2021-2026) Table 63. Global Nimodipine Sustained Release Tablets Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Nimodipine Sustained Release Tablets Sales Value Market Share by Country (2027-2032) Table 65. Arbor Pharmaceuticals Company Information Table 66. Arbor Pharmaceuticals Business Overview Table 67. Arbor Pharmaceuticals Nimodipine Sustained Release Tablets Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 68. Arbor Pharmaceuticals Nimodipine Sustained Release Tablets Product Portfolio Table 69. Arbor Pharmaceuticals Recent Development Table 70. Bayer Vital Company Information Table 71. Bayer Vital Business Overview Table 72. Bayer Vital Nimodipine Sustained Release Tablets Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 73. Bayer Vital Nimodipine Sustained Release Tablets Product Portfolio Table 74. Bayer Vital Recent Development Table 75. Bionpharma Company Information Table 76. Bionpharma Business Overview Table 77. Bionpharma Nimodipine Sustained Release Tablets Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 78. Bionpharma Nimodipine Sustained Release Tablets Product Portfolio Table 79. Bionpharma Recent Development Table 80. Heritage Pharmaceuticals Company Information Table 81. Heritage Pharmaceuticals Business Overview Table 82. Heritage Pharmaceuticals Nimodipine Sustained Release Tablets Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 83. Heritage Pharmaceuticals Nimodipine Sustained Release Tablets Product Portfolio Table 84. Heritage Pharmaceuticals Recent Development Table 85. Pharmaceutics International Company Information Table 86. Pharmaceutics International Business Overview Table 87. Pharmaceutics International Nimodipine Sustained Release Tablets Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. Pharmaceutics International Nimodipine Sustained Release Tablets Product Portfolio Table 89. Pharmaceutics International Recent Development Table 90. Sofgen Pharmaceuticals Company Information Table 91. Sofgen Pharmaceuticals Business Overview Table 92. Sofgen Pharmaceuticals Nimodipine Sustained Release Tablets Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Sofgen Pharmaceuticals Nimodipine Sustained Release Tablets Product Portfolio Table 94. Sofgen Pharmaceuticals Recent Development Table 95. Wuhan HITECK Biopharmaceutical Company Information Table 96. Wuhan HITECK Biopharmaceutical Business Overview Table 97. Wuhan HITECK Biopharmaceutical Nimodipine Sustained Release Tablets Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Wuhan HITECK Biopharmaceutical Nimodipine Sustained Release Tablets Product Portfolio Table 99. Wuhan HITECK Biopharmaceutical Recent Development Table 100. Sihuan Pharmaceutical Company Information Table 101. Sihuan Pharmaceutical Business Overview Table 102. Sihuan Pharmaceutical Nimodipine Sustained Release Tablets Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. Sihuan Pharmaceutical Nimodipine Sustained Release Tablets Product Portfolio Table 104. Sihuan Pharmaceutical Recent Development Table 105. Jiangsu Kanion Pharmaceutical Company Information Table 106. Jiangsu Kanion Pharmaceutical Business Overview Table 107. Jiangsu Kanion Pharmaceutical Nimodipine Sustained Release Tablets Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. Jiangsu Kanion Pharmaceutical Nimodipine Sustained Release Tablets Product Portfolio Table 109. Jiangsu Kanion Pharmaceutical Recent Development Table 110. Qilu Pharmaceutical Company Information Table 111. Qilu Pharmaceutical Business Overview Table 112. Qilu Pharmaceutical Nimodipine Sustained Release Tablets Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 113. Qilu Pharmaceutical Nimodipine Sustained Release Tablets Product Portfolio Table 114. Qilu Pharmaceutical Recent Development Table 115. Shandong Yunmen Pharmaceutical Company Information Table 116. Shandong Yunmen Pharmaceutical Business Overview Table 117. Shandong Yunmen Pharmaceutical Nimodipine Sustained Release Tablets Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 118. Shandong Yunmen Pharmaceutical Nimodipine Sustained Release Tablets Product Portfolio Table 119. Shandong Yunmen Pharmaceutical Recent Development Table 120. Yabao Pharmaceutical Group Company Information Table 121. Yabao Pharmaceutical Group Business Overview Table 122. Yabao Pharmaceutical Group Nimodipine Sustained Release Tablets Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 123. Yabao Pharmaceutical Group Nimodipine Sustained Release Tablets Product Portfolio Table 124. Yabao Pharmaceutical Group Recent Development Table 125. Key Raw Materials Table 126. Raw Materials Key Suppliers Table 127. Nimodipine Sustained Release Tablets Distributors List Table 128. Nimodipine Sustained Release Tablets Customers List Table 129. Research Programs/Design for This Report Table 130. Authors List of This Report Table 131. Secondary Sources Table 132. Primary Sources List of Figures Figure 1. Nimodipine Sustained Release Tablets Product Image Figure 2. Global Nimodipine Sustained Release Tablets Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Nimodipine Sustained Release Tablets Sales Value (2021-2032) & (US$ Million) Figure 4. Global Nimodipine Sustained Release Tablets Sales (2021-2032) & (K Units) Figure 5. Global Nimodipine Sustained Release Tablets Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Nimodipine Sustained Release Tablets Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. 30mg/Piece Image Figure 10. 60mg/Piece Image Figure 11. Others Image Figure 12. Global Nimodipine Sustained Release Tablets Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 13. Global Nimodipine Sustained Release Tablets Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Nimodipine Sustained Release Tablets Sales Volume Share by Type (2021-2032) Figure 15. Global Nimodipine Sustained Release Tablets Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Nimodipine Sustained Release Tablets Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Nimodipine Sustained Release Tablets Sales Value Share by Type (2021-2032) Figure 18. Hospital Image Figure 19. Pharmacy Image Figure 20. Others Image Figure 21. Global Nimodipine Sustained Release Tablets Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global Nimodipine Sustained Release Tablets Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Nimodipine Sustained Release Tablets Sales Volume Share by Application (2021-2032) Figure 24. Global Nimodipine Sustained Release Tablets Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Nimodipine Sustained Release Tablets Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Nimodipine Sustained Release Tablets Sales Value Share by Application (2021-2032) Figure 27. Global Nimodipine Sustained Release Tablets Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 28. Global Nimodipine Sustained Release Tablets Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Nimodipine Sustained Release Tablets Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Nimodipine Sustained Release Tablets Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Nimodipine Sustained Release Tablets Sales Value (2021-2032) & (US$ Million) Figure 32. North America Nimodipine Sustained Release Tablets Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Nimodipine Sustained Release Tablets Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Nimodipine Sustained Release Tablets Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Nimodipine Sustained Release Tablets Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Nimodipine Sustained Release Tablets Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Nimodipine Sustained Release Tablets Sales Value (2021-2032) & (US$ Million) Figure 38. South America Nimodipine Sustained Release Tablets Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Nimodipine Sustained Release Tablets Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Nimodipine Sustained Release Tablets Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Nimodipine Sustained Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Nimodipine Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Nimodipine Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Nimodipine Sustained Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Nimodipine Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Nimodipine Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Nimodipine Sustained Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Nimodipine Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Nimodipine Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Nimodipine Sustained Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Nimodipine Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Nimodipine Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Nimodipine Sustained Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Nimodipine Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Nimodipine Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Nimodipine Sustained Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Nimodipine Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Nimodipine Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Nimodipine Sustained Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Nimodipine Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Nimodipine Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Nimodipine Sustained Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Nimodipine Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Nimodipine Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Nimodipine Sustained Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Nimodipine Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Nimodipine Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Nimodipine Sustained Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Nimodipine Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Nimodipine Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Nimodipine Sustained Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Nimodipine Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Nimodipine Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Nimodipine Sustained Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Nimodipine Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Nimodipine Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Nimodipine Sustained Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Nimodipine Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Nimodipine Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Nimodipine Sustained Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Nimodipine Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Nimodipine Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Nimodipine Sustained Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Nimodipine Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Nimodipine Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Nimodipine Sustained Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Nimodipine Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Nimodipine Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Nimodipine Sustained Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Nimodipine Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Nimodipine Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Nimodipine Sustained Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Nimodipine Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Nimodipine Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Nimodipine Sustained Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Nimodipine Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Nimodipine Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Nimodipine Sustained Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Nimodipine Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Nimodipine Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Nimodipine Sustained Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Nimodipine Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Nimodipine Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Nimodipine Sustained Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Nimodipine Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Nimodipine Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Nimodipine Sustained Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Nimodipine Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Nimodipine Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Nimodipine Sustained Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Nimodipine Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Nimodipine Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Nimodipine Sustained Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Nimodipine Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Nimodipine Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Nimodipine Sustained Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Nimodipine Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Nimodipine Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Nimodipine Sustained Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Nimodipine Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Nimodipine Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Nimodipine Sustained Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Nimodipine Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Nimodipine Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Nimodipine Sustained Release Tablets Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Nimodipine Sustained Release Tablets Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • 30mg/Piece
  • 60mg/Piece
  • Others
Applications
  • Hospital
  • Pharmacy
  • Others
Companies covered
  • Arbor Pharmaceuticals
  • Bayer Vital
  • Bionpharma
  • Heritage Pharmaceuticals
  • Pharmaceutics International
  • Sofgen Pharmaceuticals
  • Wuhan HITECK Biopharmaceutical
  • Sihuan Pharmaceutical
  • Jiangsu Kanion Pharmaceutical
  • Qilu Pharmaceutical
  • Shandong Yunmen Pharmaceutical
  • Yabao Pharmaceutical Group

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Nimodipine Sustained Release Tablets Sales Value (2021-2032)
  4. 1.2.2 Global Nimodipine Sustained Release Tablets Sales Volume (2021-2032)
  5. 1.2.3 Global Nimodipine Sustained Release Tablets Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Nimodipine Sustained Release Tablets Market Dynamics
  1. 2.1 Nimodipine Sustained Release Tablets Industry Trends
  2. 2.2 Nimodipine Sustained Release Tablets Industry Drivers
  3. 2.3 Nimodipine Sustained Release Tablets Industry Opportunities and Challenges
  4. 2.4 Nimodipine Sustained Release Tablets Industry Restraints
3 Nimodipine Sustained Release Tablets Market by Company
  1. 3.1 Global Nimodipine Sustained Release Tablets Company Revenue Ranking in 2025
  2. 3.2 Global Nimodipine Sustained Release Tablets Revenue by Company (2021-2026)
  3. 3.3 Global Nimodipine Sustained Release Tablets Sales Volume by Company (2021-2026)
  4. 3.4 Global Nimodipine Sustained Release Tablets Average Price by Company (2021-2026)
  5. 3.5 Global Nimodipine Sustained Release Tablets Company Ranking (2024-2026)
  6. 3.6 Global Nimodipine Sustained Release Tablets Company Manufacturing Base and Headquarters
  7. 3.7 Global Nimodipine Sustained Release Tablets Company Product Type and Application
  8. 3.8 Global Nimodipine Sustained Release Tablets Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Nimodipine Sustained Release Tablets Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Nimodipine Sustained Release Tablets Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Nimodipine Sustained Release Tablets Market by Type
  1. 4.1 Nimodipine Sustained Release Tablets Type Introduction
  2. 4.1.1 30mg/Piece
  3. 4.1.2 60mg/Piece
  4. 4.1.3 Others
  5. 4.2 Global Nimodipine Sustained Release Tablets Sales Volume by Type
  6. 4.2.1 Global Nimodipine Sustained Release Tablets Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Nimodipine Sustained Release Tablets Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Nimodipine Sustained Release Tablets Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Nimodipine Sustained Release Tablets Sales Value by Type
  10. 4.3.1 Global Nimodipine Sustained Release Tablets Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Nimodipine Sustained Release Tablets Sales Value by Type (2021-2032)
  12. 4.3.3 Global Nimodipine Sustained Release Tablets Sales Value Share by Type (2021-2032)
5 Nimodipine Sustained Release Tablets Market by Application
  1. 5.1 Nimodipine Sustained Release Tablets Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Pharmacy
  4. 5.1.3 Others
  5. 5.2 Global Nimodipine Sustained Release Tablets Sales Volume by Application
  6. 5.2.1 Global Nimodipine Sustained Release Tablets Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Nimodipine Sustained Release Tablets Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Nimodipine Sustained Release Tablets Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Nimodipine Sustained Release Tablets Sales Value by Application
  10. 5.3.1 Global Nimodipine Sustained Release Tablets Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Nimodipine Sustained Release Tablets Sales Value by Application (2021-2032)
  12. 5.3.3 Global Nimodipine Sustained Release Tablets Sales Value Share by Application (2021-2032)
6 Nimodipine Sustained Release Tablets Regional Sales and Value Analysis
  1. 6.1 Global Nimodipine Sustained Release Tablets Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Nimodipine Sustained Release Tablets Sales by Region (2021-2032)
  3. 6.2.1 Global Nimodipine Sustained Release Tablets Sales by Region: 2021-2026
  4. 6.2.2 Global Nimodipine Sustained Release Tablets Sales by Region (2027-2032)
  5. 6.3 Global Nimodipine Sustained Release Tablets Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Nimodipine Sustained Release Tablets Sales Value by Region (2021-2032)
  7. 6.4.1 Global Nimodipine Sustained Release Tablets Sales Value by Region: 2021-2026
  8. 6.4.2 Global Nimodipine Sustained Release Tablets Sales Value by Region (2027-2032)
  9. 6.5 Global Nimodipine Sustained Release Tablets Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Nimodipine Sustained Release Tablets Sales Value (2021-2032)
  12. 6.6.2 North America Nimodipine Sustained Release Tablets Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Nimodipine Sustained Release Tablets Sales Value (2021-2032)
  15. 6.7.2 Europe Nimodipine Sustained Release Tablets Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Nimodipine Sustained Release Tablets Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Nimodipine Sustained Release Tablets Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Nimodipine Sustained Release Tablets Sales Value (2021-2032)
  21. 6.9.2 South America Nimodipine Sustained Release Tablets Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Nimodipine Sustained Release Tablets Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Nimodipine Sustained Release Tablets Sales Value Share by Country, 2025 VS 2032
7 Nimodipine Sustained Release Tablets Country-level Sales and Value Analysis
  1. 7.1 Global Nimodipine Sustained Release Tablets Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Nimodipine Sustained Release Tablets Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Nimodipine Sustained Release Tablets Sales by Country (2021-2032)
  4. 7.3.1 Global Nimodipine Sustained Release Tablets Sales by Country (2021-2026)
  5. 7.3.2 Global Nimodipine Sustained Release Tablets Sales by Country (2027-2032)
  6. 7.4 Global Nimodipine Sustained Release Tablets Sales Value by Country (2021-2032)
  7. 7.4.1 Global Nimodipine Sustained Release Tablets Sales Value by Country (2021-2026)
  8. 7.4.2 Global Nimodipine Sustained Release Tablets Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Nimodipine Sustained Release Tablets Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Nimodipine Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Nimodipine Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Nimodipine Sustained Release Tablets Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Nimodipine Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Nimodipine Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Nimodipine Sustained Release Tablets Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Nimodipine Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Nimodipine Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Nimodipine Sustained Release Tablets Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Nimodipine Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Nimodipine Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Nimodipine Sustained Release Tablets Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Nimodipine Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Nimodipine Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Nimodipine Sustained Release Tablets Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Nimodipine Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Nimodipine Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Nimodipine Sustained Release Tablets Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Nimodipine Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Nimodipine Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Nimodipine Sustained Release Tablets Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Nimodipine Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Nimodipine Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Nimodipine Sustained Release Tablets Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Nimodipine Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Nimodipine Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Nimodipine Sustained Release Tablets Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Nimodipine Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Nimodipine Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Nimodipine Sustained Release Tablets Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Nimodipine Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Nimodipine Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Nimodipine Sustained Release Tablets Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Nimodipine Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Nimodipine Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Nimodipine Sustained Release Tablets Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Nimodipine Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Nimodipine Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Nimodipine Sustained Release Tablets Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Nimodipine Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Nimodipine Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Nimodipine Sustained Release Tablets Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Nimodipine Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Nimodipine Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Nimodipine Sustained Release Tablets Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Nimodipine Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Nimodipine Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Nimodipine Sustained Release Tablets Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Nimodipine Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Nimodipine Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Nimodipine Sustained Release Tablets Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Nimodipine Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Nimodipine Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Nimodipine Sustained Release Tablets Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Nimodipine Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Nimodipine Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Nimodipine Sustained Release Tablets Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Nimodipine Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Nimodipine Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Nimodipine Sustained Release Tablets Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Nimodipine Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Nimodipine Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Nimodipine Sustained Release Tablets Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Nimodipine Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Nimodipine Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Nimodipine Sustained Release Tablets Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Nimodipine Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Nimodipine Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Nimodipine Sustained Release Tablets Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Nimodipine Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Nimodipine Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Nimodipine Sustained Release Tablets Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Nimodipine Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Nimodipine Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Nimodipine Sustained Release Tablets Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Nimodipine Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Nimodipine Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Nimodipine Sustained Release Tablets Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Nimodipine Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Nimodipine Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Nimodipine Sustained Release Tablets Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Nimodipine Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Nimodipine Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Arbor Pharmaceuticals
  2. 8.1.1 Arbor Pharmaceuticals Company Information
  3. 8.1.2 Arbor Pharmaceuticals Business Overview
  4. 8.1.3 Arbor Pharmaceuticals Nimodipine Sustained Release Tablets Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Arbor Pharmaceuticals Nimodipine Sustained Release Tablets Product Portfolio
  6. 8.1.5 Arbor Pharmaceuticals Recent Developments
  7. 8.2 Bayer Vital
  8. 8.2.1 Bayer Vital Company Information
  9. 8.2.2 Bayer Vital Business Overview
  10. 8.2.3 Bayer Vital Nimodipine Sustained Release Tablets Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Bayer Vital Nimodipine Sustained Release Tablets Product Portfolio
  12. 8.2.5 Bayer Vital Recent Developments
  13. 8.3 Bionpharma
  14. 8.3.1 Bionpharma Company Information
  15. 8.3.2 Bionpharma Business Overview
  16. 8.3.3 Bionpharma Nimodipine Sustained Release Tablets Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Bionpharma Nimodipine Sustained Release Tablets Product Portfolio
  18. 8.3.5 Bionpharma Recent Developments
  19. 8.4 Heritage Pharmaceuticals
  20. 8.4.1 Heritage Pharmaceuticals Company Information
  21. 8.4.2 Heritage Pharmaceuticals Business Overview
  22. 8.4.3 Heritage Pharmaceuticals Nimodipine Sustained Release Tablets Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Heritage Pharmaceuticals Nimodipine Sustained Release Tablets Product Portfolio
  24. 8.4.5 Heritage Pharmaceuticals Recent Developments
  25. 8.5 Pharmaceutics International
  26. 8.5.1 Pharmaceutics International Company Information
  27. 8.5.2 Pharmaceutics International Business Overview
  28. 8.5.3 Pharmaceutics International Nimodipine Sustained Release Tablets Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Pharmaceutics International Nimodipine Sustained Release Tablets Product Portfolio
  30. 8.5.5 Pharmaceutics International Recent Developments
  31. 8.6 Sofgen Pharmaceuticals
  32. 8.6.1 Sofgen Pharmaceuticals Company Information
  33. 8.6.2 Sofgen Pharmaceuticals Business Overview
  34. 8.6.3 Sofgen Pharmaceuticals Nimodipine Sustained Release Tablets Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Sofgen Pharmaceuticals Nimodipine Sustained Release Tablets Product Portfolio
  36. 8.6.5 Sofgen Pharmaceuticals Recent Developments
  37. 8.7 Wuhan HITECK Biopharmaceutical
  38. 8.7.1 Wuhan HITECK Biopharmaceutical Company Information
  39. 8.7.2 Wuhan HITECK Biopharmaceutical Business Overview
  40. 8.7.3 Wuhan HITECK Biopharmaceutical Nimodipine Sustained Release Tablets Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Wuhan HITECK Biopharmaceutical Nimodipine Sustained Release Tablets Product Portfolio
  42. 8.7.5 Wuhan HITECK Biopharmaceutical Recent Developments
  43. 8.8 Sihuan Pharmaceutical
  44. 8.8.1 Sihuan Pharmaceutical Company Information
  45. 8.8.2 Sihuan Pharmaceutical Business Overview
  46. 8.8.3 Sihuan Pharmaceutical Nimodipine Sustained Release Tablets Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Sihuan Pharmaceutical Nimodipine Sustained Release Tablets Product Portfolio
  48. 8.8.5 Sihuan Pharmaceutical Recent Developments
  49. 8.9 Jiangsu Kanion Pharmaceutical
  50. 8.9.1 Jiangsu Kanion Pharmaceutical Company Information
  51. 8.9.2 Jiangsu Kanion Pharmaceutical Business Overview
  52. 8.9.3 Jiangsu Kanion Pharmaceutical Nimodipine Sustained Release Tablets Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Jiangsu Kanion Pharmaceutical Nimodipine Sustained Release Tablets Product Portfolio
  54. 8.9.5 Jiangsu Kanion Pharmaceutical Recent Developments
  55. 8.10 Qilu Pharmaceutical
  56. 8.10.1 Qilu Pharmaceutical Company Information
  57. 8.10.2 Qilu Pharmaceutical Business Overview
  58. 8.10.3 Qilu Pharmaceutical Nimodipine Sustained Release Tablets Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Qilu Pharmaceutical Nimodipine Sustained Release Tablets Product Portfolio
  60. 8.10.5 Qilu Pharmaceutical Recent Developments
  61. 8.11 Shandong Yunmen Pharmaceutical
  62. 8.11.1 Shandong Yunmen Pharmaceutical Company Information
  63. 8.11.2 Shandong Yunmen Pharmaceutical Business Overview
  64. 8.11.3 Shandong Yunmen Pharmaceutical Nimodipine Sustained Release Tablets Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Shandong Yunmen Pharmaceutical Nimodipine Sustained Release Tablets Product Portfolio
  66. 8.11.5 Shandong Yunmen Pharmaceutical Recent Developments
  67. 8.12 Yabao Pharmaceutical Group
  68. 8.12.1 Yabao Pharmaceutical Group Company Information
  69. 8.12.2 Yabao Pharmaceutical Group Business Overview
  70. 8.12.3 Yabao Pharmaceutical Group Nimodipine Sustained Release Tablets Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Yabao Pharmaceutical Group Nimodipine Sustained Release Tablets Product Portfolio
  72. 8.12.5 Yabao Pharmaceutical Group Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Nimodipine Sustained Release Tablets Value Chain Analysis
  2. 9.1.1 Nimodipine Sustained Release Tablets Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Nimodipine Sustained Release Tablets Sales Mode & Process
  6. 9.2 Nimodipine Sustained Release Tablets Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Nimodipine Sustained Release Tablets Distributors
  9. 9.2.3 Nimodipine Sustained Release Tablets Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst